Peptide Hydrogel for Sustained Release of Bone Morphogenetic Protein
Author Information
Author(s): Wang Dalin, Qi Guangyan, Zhang Mingcai, Carlson Brandon, Gernon Matthew, Burton Douglas, Sun Xiuzhi Susan, Wang Jinxi
Primary Institution: University of Kansas Medical Center
Hypothesis
Varying the formulation of a specific peptide hydrogel (PepGel) can control the release kinetics of rhBMP-2 in vitro.
Conclusion
The study indicates that a 50% v/v PepGel formulation provides a sustained release of rhBMP-2 over 21 days, which could reduce adverse effects in clinical applications.
Supporting Evidence
- 50% v/v PepGel showed sustained release of rhBMP-2 over 21 days.
- 67% and 80% v/v PepGels had significantly lower release rates after day 7.
- Higher gel porosity correlated with increased rhBMP-2 release rates.
- The swelling ratio and elastic modulus of the 50% v/v PepGel were significantly lower than those of the higher concentrations.
Takeaway
This study shows that changing the recipe of a special gel can help medicine be released slowly and safely in the body, which is important for healing bones.
Methodology
The study tested three PepGel formulations with different concentrations to assess their impact on the release of rhBMP-2 over 21 days using ELISA.
Limitations
The study was conducted in vitro, lacking the complexity of in vivo conditions.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website